HDAC9 and Sepsis: Although the therapeutic benefits of HDAC inhibitors in cancer and inflammatory diseases have been associated with various metabolic processes [34], the relationship between the acetylation of glycolytic enzymes and its effects on innate immune cells in sepsis remains poorly understood.